Exabis Library
Welcome to the e-CCO Library!
P489: Defective anti-microbial peptides expression in Crohn’s disease mucosa can be reversed by strengthening IL-22 signalling
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P489: Double-dose infliximab therapy in Crohn's disease: appropriate time to evaluate the efficacy, long-term efficacy and safety
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P489: Predicting mucosal state with faecal calprotectin in children with Crohn’s disease.
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P489: Rescue treatment with original versus biosimilar infliximab in biologic-naïve patients with moderate-severe Ulcerative Colitis and corticosteroid failure
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P489: Surgery for enterocutaneous fistula: the strongest predictor of postoperative mortality in Crohn's disease patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P489: Temporal trends of colectomy for ulcerative colitis in the multi-drug era; a population based cohort study.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P490 Assessment of body weight changes in patients with inflammatory bowel diseases initiating biologic therapy: A prospective cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P490: A pilot study of the electronic patient portal “Patient Knows Best” for monitoring biologic therapy in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P490: A vedolizumab population pharmacokinetic model including intravenous and subcutaneous formulations for patients with ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P490: Clinicians’ adherence to European Crohn’s and Colitis Organisation guidelines in the clinical care of adults with inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P490: Drug survival and immunogenicity after switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: Two-year follow-up of a prospective observational cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P490: Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P490: Patients with inflammatory bowel disease should be vaccinated against pneumococcus and influenza despite immunosuppressive therapy
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P490: The impact of the COVID-19 pandemic on gastroenterologists providing care to inflammatory bowel disease patients in Canada: preliminary data of a cross-sectional survey
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P491 De-escalation of dose-intensified anti-TNF therapy in IBD patients in sustained deep remission
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P491: Comparative efficacy on mucosal healing of pharmacological therapies for moderate-to-severe ulcerative colitis, based on prior exposure to tumour necrosis factor antagonists: A systematic review and network meta-analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P491: Comparison of the durability of response to subcutaneous anti-TNF therapy between ulcerative colitis and Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P491: Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P491: Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTE
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P491: In patients with active ulcerative colitis, cytapheresis spares corticosteroids, and reduces hospitalisation time: therapeutic outcomes in 181 consecutive patients.
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM